Digital Commons Network^™

Initial Experience With The Next-Generation Resolute Onyx Zotarolimus-Eluting Stent In Symptomatic Intracranial Atherosclerotic Disease, Ameer E. Hassan, Mahmoud H. Mohammaden, Rani R. Rabah, Wondwossen G. Tekle

School of Medicine Publications and Presentations

Background and Purpose: Intracranial atherosclerotic disease (ICAD) is a common cause of stroke worldwide. Although there are different endovascular options for the treatment of symptomatic ICAD (sICAD), it is still controversial. Herein, we aim to study the safety and efficacy of a new generation of drug-eluting balloon-mounted stent (DES); Resolute (R) onyx DES in the treatment of sICAD.

Methods:A prospectively maintained neuroendovascular procedures database in a high-volume comprehensive stroke center was reviewed from October 2019 through January 2020. Patients were included if they had sICAD (≥70% stenosis), failed medical management, and underwent intracranial stenting with R-onyx DES. Technical success …

Superior Short-Term Patency Of Stents Over Balloons In Infrapopliteal Artery Disease, Supraja Thunuguntla, Obinna Echeruo, Charles Mild

School of Medicine Publications and Presentations

Purpose

The optimal strategy for revascularization in below-the-knee (BTK) chronic limb-threatening ischemia (CLTI) remains debatable. High restenosis rates of percutaneous transluminal angioplasty (PTA) often warrants re-intervention or amputations. Novel devices such as drug-eluting (paclitaxel) balloons (DEB), stents, and atherectomy devices- directional (HawkOne, SilverHawk, TurboHawk)™ or orbital (DiamondBack 360) ™ are used infrequently as therapy when BTK. We aim to compare the rate of total re-occlusion between these interventions.

Material & Methods

A retrospective chart review of 97 patients who underwent BTK percutaneous intervention in 2015-2020 at our hospital. Descriptive statistics were used to assess the distribution of variables; continuous variables …